Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Open-Label Multicenter Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer (MIBC)

Next Previous
Trial Profile

A Phase I/II Open-Label Multicenter Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer (MIBC)

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 27 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nitroxoline (Primary) ; Tislelizumab (Primary)
  • Indications Bladder cancer; Carcinoma
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms ANTICIPATE
  • Sponsors Jiangsu Yahong Pharmaceutical Technology

Most Recent Events

  • 18 Apr 2025 According to an Asieris Pharmaceuticals media release, the Phase II clinical trial of oral APL-1202 in combination with tislelizumab as a neoadjuvant therapy for muscle-invasive bladder cancer (MIBC) was successfully completed in September 2024, delivering encouraging efficacy signals.
  • 28 Aug 2024 According to an Asieris Pharmaceuticals media release, data read-out from the phase II trial is expected in September 2024.
  • 29 Jan 2024 According to an Asieris Pharmaceuticals media release, interim data from this study presented at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top